ArticleNPJ Parkinson's disease2025
Systematic review and consensus conceptual model of meaningful symptoms and functional impacts in early Parkinson's Disease.
Article in NPJ Parkinson's disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Research advances in the microbiota‑gut‑brain axis and Parkinson's disease (Review).Molecular medicine reports · 2026Review
- Exploring the Neuropharmacological Potential of Ligustrum sinense Relevant to Parkinson's Disease: In Vivo and In Silico Study.Chemistry & biodiversity · 2026Article
- Modeling Framework for Economic Evaluation of Disease-Modifying Therapies in Parkinson's Disease: Evidence Review and Expert Opinion.PharmacoEconomics · 2026Article
- Daily-Life, Sensor-Derived Tremor Measures Are Sensitive to Progression in Early Parkinson's Disease.Annals of neurology · 2026Article
- Hoehn and Yahr Stage and Non-Motor Symptom Burden in Parkinson's Disease: A Cross-Sectional Study in Peru.Medicina (Kaunas, Lithuania) · 2026Article
- LiquidGAN for Handwriting-Based Detection and Severity Classification of Extrapyramidal Symptoms.Sensors (Basel, Switzerland) · 2026Article
- Wearable-sensor based walking and non-walking measures as progression markers in early to mid-stage Parkinson's disease.NPJ Parkinson's disease · 2026Article
- Evolution of Clinical Trial Design in ADPKD.Kidney international reports · 2026Review
- Three years later: tracking bothersome symptoms and impacts for people with early Parkinson's disease.Journal of neurology · 2026Article
- Three years later: tracking bothersome symptoms and impacts for people with early Parkinson's disease.Journal of neurology · 2026Article
- Sex-specific gray matter underpinnings of anxiety and their mediating mechanisms inFrontiers in aging neuroscience · 2026Article
- Neuroimmune crosstalk in Parkinson's disease: the pivotal role of microglia and infiltrating T cells.Molecular biology reports · 2025Review
- A network analysis study of anxiety, depression and loneliness among middle-aged and elderly people in Xining area.BMC psychology · 2025Article
- Longitudinal qualitative assessment of meaningful symptoms and relevance of WATCH-PD digital measures for people with early Parkinson's.Journal of neurology · 2025Article
- Development and emerging trends in gastrointestinal dysfunction of Parkinson's disease: a decade-long bibliometric analysis.Frontiers in aging neuroscience · 2025Review
- Understanding what aspects of Parkinson's disease matter most to patients and families.Scientific reports · 2024Article
- Stage-specific digital health technology biomarkers enhance diagnostic and early progression detection in Parkinson's disease.Frontiers in neurologyArticle
- Using Digital Outcomes to Measure Meaningful Aspects of Health in Clinical Trials for Parkinson's Disease: A Scoping Review.Digital biomarkersReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A comprehensive, patient-centered conceptual model of early Parkinson's is lacking and is greatly needed. A systematic review and meta-synthesis of qualitative and quantitative research was conducted by a multi-stakeholder taskforce using JBI Mixed Methods Review criteria and GRADE-CERQual standards for assessment of evidence. Over 340 symptoms and impacts were identified across ten symptom domains (Movement, Cognitive, Psychiatric, Sleep, Sensory, Speech, Digestive, Urinary, Sexual, Autonomic) and two impact domains (Physical and Psychosocial functioning). A wide range of motor and non-motor symptoms were present in early disease, with strongest support for tremor, dexterity, gait, stiffness, slow movements, cognitive, mood, and sleep alterations, urinary dysfunction, constipation, pain, and fatigue. These affected mobility, self-concept, coping, effort of living, interactions and important activities, with evidence of many understudied concepts. This model offers the most comprehensive catalogue of symptoms and impacts in Parkinson's to date and will support clinical practice and endpoint selection for therapeutic trials.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.